AngioDynamics, Inc. (ANGO) Scheduled to Post Quarterly Earnings on Tuesday
AngioDynamics, Inc. (NASDAQ:ANGO) is set to issue its quarterly earnings data before the market opens on Tuesday, October 3rd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. AngioDynamics has set its FY18 guidance at $0.64-0.68 EPS.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The company had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. During the same quarter last year, the firm posted $0.19 EPS. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, analysts expect AngioDynamics to post $0.67 EPS for the current fiscal year and $0.74 EPS for the next fiscal year.
AngioDynamics, Inc. (NASDAQ ANGO) opened at 17.93 on Tuesday. The stock’s 50 day moving average is $17.00 and its 200 day moving average is $16.31. The company has a market cap of $655.88 million, a price-to-earnings ratio of 130.88 and a beta of 1.14. AngioDynamics, Inc. has a 52-week low of $14.80 and a 52-week high of $18.35.
A number of analysts recently commented on the company. BidaskClub upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. KeyCorp reiterated a “hold” rating on shares of AngioDynamics in a research report on Friday, August 25th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a research report on Tuesday, July 18th. Finally, Cantor Fitzgerald lifted their price objective on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $18.60.
In related news, CEO James C. Clemmer bought 20,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was bought at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James C. Clemmer bought 5,000 shares of the firm’s stock in a transaction dated Friday, July 21st. The shares were bought at an average price of $15.79 per share, with a total value of $78,950.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders have bought a total of 25,316 shares of company stock valued at $396,806 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.